Posts Tagged ‘drug labeling’

Obesity Care Week: Correct Drug Labeling for People with Obesity

March 5, 2025 — FDA seems to be moving toward giving more and more attention to accurate drug labeling for people with obesity. Yesterday, Medscape published a deep exploration of this issue. The timing coincided nicely with Obesity Care Week and World Obesity Day, Responding to Medscape Medical News, FDA made reference to a workshop they sponsored on the […]

Growing Calls for Drug Labels to Include People with Obesity

February 4, 2025 — Chasing the possibility of multi-billion dollar obesity medicines, pharmaceutical companies are jumping at the chance to spend billions in clinical research. But patient advocates find a reluctance from some of those same companies to take people with obesity into account in the drug labels for their products already on the market. Writing for In Vivo, […]

OW2024: A Blind Spot in Drug Labeling for Persons with Obesity

November 16, 2024 — Research presented at ObesityWeek 2024 shines a light on a blind spot in drug labeling for persons with obesity. No, we’re not talking about the latest buzzy drug for treating obesity. Rather, we are talking about a prime example of labeling for other drugs that people with obesity may need when they face a serious […]

Leaving Doctors in the Dark About Patients with Obesity

October 29, 2024 — In some ways, it is nothing new. The medical needs of people living with obesity have been dismissed seemingly forever. But at the same time it is shocking to learn of Merck – a highly respected pharmaceutical firm – leaving doctors in the dark by choice about how one of their drugs acts differently in […]

Losing Patience with Drug Labels Dismissing People with Obesity

September 9, 2024 — The American College of Clinical Pharmacology is meeting in Bethesda this week. On the opening day, ACCP convened a symposium to address critical questions about how drugs work in people with obesity. What can we – industry, FDA, and scientists – do better? Because all too often, drug labels to guide safe prescribing are effectively […]

FDA Faces Questions About Drug Safety for People with Obesity

May 24, 2024 — At a hearing this week fo the U.S. House Committee on Energy and Commerce, Representative Robin Kelly asked the Director of the FDA Center for Drug Evaluation and Research, Patrizia Cavazzoni, what the agency is doing to ensure that drug labeling adequately protects the safety of people with obesity: “Patients with obesity are frequently excluded […]

More Calls for People with Obesity in Drug Trials and Labels

January 26, 2024 — The calls are growing louder and more frequent to include people living with obesity in clinical trials and drug labels. Of course trials and labels for drugs that treat obesity include these patients. But the huge problem is that for everything else, more often than not, drug studies and labels exclude them. Now, the American […]

Fix the Blind Spot in Drug Trials Says Every Major Obesity Group

November 29, 2023 — It is time to translate words into action and fix the blind spot in drug trials and labeling for people with obesity. Every major obesity group in the U.S. issued this united call to action on Tuesday. This includes the ASMBS, Obesity Action Coalition, Obesity Medicine, Obesity Society, and STOP Obesity Alliance. It comes as […]

Do Cancer Drugs Work Safely for People with Obesity? Maybe

November 18, 2023 — At a time when nearly half of the U.S. population is living with obesity, this should be an easy question to answer. Obesity clearly causes some forms of cancer and as the prevalence of obesity is rising, patterns of cancer prevalence are shifting, too. So, yes, we should be able to say with great confidence […]

Drug Studies, Labels, and Dosing Only for Lean Persons?

November 8, 2023 — Public health experts have long been accounting for it. People are living in larger bodies. Better than 40% of U.S. adults have a body weight in the range of obesity. But new reporting from JoNel Aleccia for the Associated Press tells us that pharma and the FDA are not yet accounting for this fact. It’s […]